
-
Exelixis Inc NasdaqGS:EXEL Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Location: 1851 Harbor Bay Parkway, Alameda, CA, 94502, United States | Website: https://www.exelixis.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
10.77B
Cash
1.031B
Avg Qtr Burn
N/A
Short % of Float
8.06%
Insider Ownership
2.18%
Institutional Own.
94.19%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
COTELLIC (cobimetinib) Details Metastatic melanoma | Approved Quarterly sales | |
COMETRIQ (cabozantinib) Details Metastatic MTC (Medullary Thyroid Cancer) | Approved Quarterly sales | |
CABOMETYX (cabozantinib) Details Renal cell carcinoma, neuroendocrine tumors (NETs) | Approved Quarterly sales | |
CABOMETYX (cabozantinib) + atezolizumab Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | sNDA Submission | |
Zanzalintinib Details Solid tumor/s, Kidney cancer, Renal cell carcinoma | Phase 3 Data readout | |
Zanzalintinib + atezolizumab Details Solid tumor/s, Cancer, Metastatic colorectal cancer | Phase 3 Data readout | |
Zanzalintinib + KEYTRUDA (Pembrolizumab) Details Cancer, Head and neck squamous cell carcinoma | Phase 3 Data readout | |
Zanzalintinib Details Neuroendocrine tumor | Phase 3 Initiation | |
Zanzalintinib + AB521 Details Cancer, Kidney cancer, Renal cell carcinoma | Phase 1/2 Update | |
Zanzalintinib +/- atezolizumab Details Solid tumor/s, Cancer, Carcinoma | Phase 1/2 Update | |
Zanzalintinib + Nivolumab ± Relatlimab Details Solid tumor/s, Cancer | Phase 1b Data readout | |
CBX-12 Details Cancer, Solid tumor/s | Failed Discontinued | |
CABOMETYX (cabozantinib) + Nivolumab + Ipilimumab Details Cancer, Solid tumor/s, Kidney cancer | Failed Discontinued | |
XL495 Details Solid tumor/s, Cancer | Failed Discontinued |